Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering - Seite 2

If a “fundamental change” (as defined in the indenture for the notes) occurs, then noteholders may require Collegium to repurchase their notes for cash.  The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

Collegium estimates that the net proceeds from the offering will be approximately $120.4 million (or approximately $138.6 million if the underwriter fully exercises its option to purchase additional notes), after deducting the underwriting discounts and commissions and estimated offering expenses.  Collegium intends to use the net proceeds from the sale of the notes, together with cash on hand and borrowings under its credit facility, to fund the purchase price of Collegium’s previously announced acquisition of assets related to Nucynta ER and Nucynta from Assertio Therapeutics, Inc. (the “Nucynta Transaction”).  Collegium intends to use the remaining net proceeds, if any, for general corporate purposes.  The offering of notes is not contingent on the consummation of the Nucynta Transaction.  If the Nucynta Transaction does not close and Collegium does not use the proceeds to redeem the notes, Collegium intends to use the net proceeds for general corporate purposes.

Jefferies LLC is acting as the sole book-running manager for the offering.

Collegium has filed a registration statement (including a prospectus), which was declared effective on November 6, 2019, and a preliminary prospectus supplement with the Securities and Exchange Commission (the “SEC”) for the offering of the notes.  You may get these documents free by visiting EDGAR on the SEC website at www.sec.gov or by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at [e-mail].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Collegium

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts.